Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
06 sept. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
01 sept. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
17 août 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights
09 août 2023 08h00 HE
|
Nuvectis Pharma, Inc.
The Phase 1b study of NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma is ongoingNXP900 IND cleared by the US FDA, start of Phase 1a study expected in Q3 2023 ...
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
20 juin 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
15 mai 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
10 mai 2023 08h00 HE
|
Nuvectis Pharma, Inc.
Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR...
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
27 avr. 2023 10h14 HE
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is...
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
27 avr. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
18 avr. 2023 08h00 HE
|
Nuvectis Pharma, Inc.
NXP800 demonstrated robust antitumor activity in two patient-derived xenograft (“PDX”) models of cholangiocarcinomaResearch conducted by investigators from the Mayo Clinic in Rochester, MN Fort...